Leerink analyst David Risinger raised the price target on Roivant Sciences (NASDAQ: ROIV) to $42.00 (from $38.00) while maintaining a Outperform rating.

The analyst comments "We are raising our DCF-derived PT from $38 to $42, driven primarily by adding the IMVT-1402 D2T-RA indication (2035E risk-adj sales of $1.4B). ROIV showcased compelling data for IMVT-1402 in D2T-RA (difficult-to-treat rheumatoid arthritis) from the ongoing randomized withdrawal trial. IMVT-1402 demonstrated compelling ACR70 responses in heavily refractory patients, including those who had previously failed JAK and TNF therapies. We look forward to IMVT-1402 Period 2 data and initial FDA feedback in 2H26. And we remain very bullish on mosliciguat (mosli) in PH-ILD and look forward to Ph2b data in 2H. See paragraphs below for additional details. Reiterate OP rating."